Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Capital Employed (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Capital Employed for 9 consecutive years, with 0.5% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 52.0% to 0.5% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.5%, a 52.0% increase, with the full-year FY2025 number at 0.58%, up 49.0% from a year prior.
  • Return on Capital Employed was 0.5% for Q4 2025 at Rhythm Pharmaceuticals, up from 0.55% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.36% in Q2 2021 to a low of 1.12% in Q1 2024.
  • A 5-year average of 0.67% and a median of 0.63% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -56bps in 2024, then skyrocketed 52bps in 2025.
  • Rhythm Pharmaceuticals' Return on Capital Employed stood at 0.57% in 2021, then increased by 9bps to 0.52% in 2022, then decreased by -24bps to 0.64% in 2023, then crashed by -58bps to 1.01% in 2024, then surged by 51bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Return on Capital Employed are 0.5% (Q4 2025), 0.55% (Q3 2025), and 0.71% (Q2 2025).